Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative iron sucrose versus ferric carboxymaltose in elderly hip fracture patients undergoing hip replacement
ChiCTR2400092079Phase 4Not yet recruiting
- Sponsor
- Panzhihua Central Hospital
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of iron sucrose, ferric carboxymaltose and erythropoietin in anaemia and iron deficiency anemia (IDA) (4 arms), sponsored by Panzhihua Central Hospital. Primary endpoints: hemoglobin, hematocrit and 5 more. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
iron sucroseferric carboxymaltoseerythropoietin
03
Conditions
anaemiairon deficiency anemia (IDA)
Beyond the preview
Go deeper on ChiCTR2400092079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092079.